Lack of circulating megakaryoblasts in newborn peripheral blood: Development and validation of a sensitive flow cytometric detection method

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 9, 2003, Pages 721-725

  Bayliff, Sherry ^a,c   Horvatinovich, Joseph M ^b   Gong, Jerald Z ^b   Rosoff, Philip M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Down syndrome; Flow cytometry; Megakaryoblast; Transient myeloproliferative disorder

Indexed keywords

ANALYTIC METHOD; ARTICLE; DISEASE ASSOCIATION; DOWN SYNDROME; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MEGAKARYOBLAST; MYELOPROLIFERATIVE DISORDER; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRANSIENT MYELOPROLIFERATIVE DISORDER; UMBILICAL CORD BLOOD; VALIDATION PROCESS;

ANTIGENS, CD34; DOWN SYNDROME; FETAL BLOOD; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; INCIDENCE; INFANT, NEWBORN; MEGAKARYOCYTES; MYELOPROLIFERATIVE DISORDERS; PILOT PROJECTS; PRELEUKEMIA; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0041733652     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200309000-00009     Document Type: Article

References (35)

1. Krivchenia E, Huether CA, Edmonds LD, et al. Comparative epidemiology of Down syndrome in two United States population, 1970-1989. Am J Epidemiol. 1993;137:815-828.
2. National Center for Health Statistics (NCHS). Down syndrome prevalence at birth, United States, 1983-1990. MMWR. 1993;43:617-622.
3. Goodwin GA, Huether CA. Revised estimates and projections of Down syndrome births in the United States, and the effects of prenatal diagnosis utilization, 1970-2002. Prenat Diagn. 1987;7:261-271.
4. Lange BJ. Review: The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524.
5. National Center for Health Statistics (NHCS). Births: Final data for 2000. NVSR. 2002;50:1-104.
6. Mertens AC, Wen W, Davies SM, et al. Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. J Pediatr. 1998;133:617-623.
7. Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1997;28:55-76.
8. Robison LL, Nesbit ME Jr, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr. 1984;105:235-242.
9. Robison LL. Down syndrome and leukemia. Leukemia. 1992;6(Suppl 1):5-7.
10. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
11. Taub JW. Relationship of chromosome 21 and acute leukemia in children with Down syndrome. J Pediatr Hematol Oncol. 2001;23:175-178.
12. Zipursky A, Brown E, Christensen H, et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97-101.
13. Van Eys J, Flexner JM. Transient spontaneous remission in a case of untreated congenital leukemia. Am J Dis Child. 1969;118:507-514.
14. Chu JY, O'Connor DM, Gale GB, et al. Congenital leukemia: two transient regressions without treatment in one patient. Pediatrics. 1983;71:277-279.
15. Brodeur GM, Dahl GV, Williams DL, et al. Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. Blood. 1980;55:691-693.
16. Heaton DC, Fitzgerald PH, Fraser GJ, et al. Transient leukemoid proliferation of the cytogenetically unbalanced +21 cell line of a constitutional mosaic boy. Blood. 1981;57:883-887.
17. Weinberg AG, Schiller G, Windmiller J. Neonatal leukemoid reaction. An isolated manifestation of mosaic trisomy 21. Am J Dis Child. 1982;136:310-311.
18. Seibel NL, Sommer A, Miser J. Transient neonatal leukemoid reactions in mosaic trisomy 21. J Pediatr. 1984;104:251-254.
19. Hanna MD, Melvin SL, Dow LW, et al. Transient myeloproliferative syndrome in a phenotypically normal infant. Am J Pediatr Hematol Oncol. 1985;7:79-81.
20. Jones GR, Weaver M, Laug WE. Transient blastemia in phenotypically normal newborns. Am J Pediatr Hematol Oncol. 1987;9:153-157.
21. Faed MJ, Robertson J, Todd AS, et al. Trisomy 21 in transient myeloproliferative disorder. Cancer Genet Cytogenet. 1990;48:259-264.
22. Morgan R, Hecht F, Cleary ML, et al. Leukemia with Down's syndrome: translocation between chromosomes 1 and 19 in acute myelomonocytic leukemia following transient congenital myeloproliferative syndrome. Blood. 1985;66:1466-1468.
23. Kempski HM, Craze JL, Chessells JM, et al. Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: a molecular cytogenetic study. Br J Haematol. 1998;103:473-479.
24. Granzen B, Bernhard B, Reinisch I, et al. Transient myeloproliferative disorder with 11q23 aberration in two neonates with Down syndrome. Ann Hematol. 1998;77:51-54.
25. Creutzig U, Ritter J, Vormoor J, et al. [Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome]. Klin Padiatr. 1990;202:253-257.
26. Kounami S, Aoyagi N, Tsuno H, et al. Additional chromosome abnormalities in transient abnormal myelopoiesis in Down's syndrome patients. Acta Haematol. 1997;98:109-112.
27. Litz CE, Davies S, Brunning RD, et al. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia. 1995;9:1432-1439.
28. Zipursky A, Wang H, Brown EJ, et al. Interphase cytogenetic analysis of in vivo differentiation in the myelodysplasia of Down syndrome. Blood. 1994;84:2278-2282.
29. Zipursky A, Thorner P, De Harven E, et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18:163-171.
30. Gamis AS, Hilden JM. Transient myeloproliferative disorder with too few data and many unanswered questions: Does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol. 2002;24:2-5.
31. Holt SE, Brown RT, Zipursky A. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome. J Pediatr Hematol Oncol. 2002;24:14-17.
32. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
33. Fisher AM, Cockwell AE, Jacobs PA, et al. Incidence of circulating cells positive for GpIb and GpIIIa in infants with Down's syndrome. Eur J Haematol. 1994;53:46-48.
34. McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science. 1971;171:293-294.
35. Hirt A, Luethy AR, Mueller B, et al. Acute megakaryoblastic leukemia in children identified by immunological marker studies. Am J Pediatr Hematol Oncol. 1990;12:27-33.